Core Insights - Pharvaris is advancing its late-stage clinical development of deucrictibant, a novel oral bradykinin B2 receptor antagonist aimed at treating bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][18] - The company plans to present pivotal data readouts for deucrictibant in the next 18 months, highlighting its commitment to addressing unmet medical needs in this area [2][4] Prophylaxis - The ongoing Phase 2 CHAPTER-1 open-label extension study shows that oral deucrictibant maintains a low attack rate for over a year and a half, regardless of baseline attack rates [3] - Participants in the CHAPTER-1 study reported significant improvements in health-related quality of life (HRQoL) and treatment satisfaction, with all participants indicating well-controlled HAE [4] - A pharmacokinetics study demonstrated that the extended-release (XR) formulation of deucrictibant supports once-daily dosing, showing a four-fold higher mean plasma concentration than the therapeutic threshold at 24 hours [5][7] On-Demand Treatment - A post-hoc analysis of the RAPIDe-1 and RAPIDe-2 trials indicated that 95-100% of HAE attacks treated with a single dose of deucrictibant achieved symptom relief without recurrence [9] - The median time to onset of symptom relief was reported as 1.1 hours, with 97.8% of attacks achieving relief within 12 hours [10][11] - Deucrictibant was well tolerated across various attack types, including upper airway attacks, with no treatment-related adverse events reported [11] Expansion Beyond HAE - Pharvaris is exploring a novel biomarker assay for diagnosing bradykinin-mediated angioedema, which could enhance the identification and management of related conditions [12] - The company is also assessing the patient experience and outcome measures for AAE-C1INH, aiming to develop a conceptual model to support clinical assessments [14] - A systematic literature review estimated the prevalence of HAE-C1INH in the EU and UK to be between 0.05-0.33 per 10,000 individuals, indicating a significant need for effective treatments [15]

Core Viewpoint - Patagonia Gold Corp. has successfully completed a US$40 million investment from Black River Mine Inc. for the development of its Calcatreu project in Argentina [1][2]. Financing Details - The investment, referred to as the Calcatreu Financing, involved the issuance of 40 million preferred shares at a price of US$1.00 per share [1]. - Proceeds from the financing will be exclusively used for the development of the Calcatreu project and related expenses [2]. - No finder's fee was paid in connection with the financing, and the preferred shares are non-voting with transfer restrictions [3]. Related Party Transaction - Black River, controlled by Carlos J. Miguens, is considered a related party, owning 43.2% of Patagonia's common shares [4]. - The financing was classified as a "related party transaction" under Multilateral Instrument 61-101, requiring shareholder approval, which was obtained at a special meeting held on May 20, 2025 [4]. Project Overview - The Calcatreu project is located in Rio Negro province, approximately 85 kilometers south of Ing Jacobacci [5]. - Patagonia acquired the project from Pan American Silver in 2018 and has since been focused on obtaining necessary permits for development [6]. - The project has an estimated 746,000 contained AuEq ounces in measured and indicated resources and 390,000 contained AuEq ounces in inferred resources [7]. Technical Information - The scientific and technical information in the news release has been reviewed and approved by Donald J. Birak, a qualified person as defined by National Instrument 43-101 [8]. - Additional details about the project and mineral resources are available in the technical report dated December 31, 2018 [9]. Company Background - Patagonia Gold Corp. is a publicly traded mining company focused on gold and silver projects in South America, primarily the Calcatreu project and the Cap-Oeste underground project [10][11].

Core Viewpoint - Codere Online has filed its annual report on form 20-F for the year ended December 31, 2024, with the SEC, indicating a step towards compliance with Nasdaq Listing Rule 5250(c)(1) [1][2]. Company Overview - Codere Online is a leading online gaming operator in Spain and Latin America, launched in 2014 as part of the Codere Group, which is known for its casino operations [5]. - The company offers online sports betting and casino services through its website and mobile applications, operating in key markets including Spain, Mexico, Colombia, Panama, and Argentina [5]. Compliance and Regulatory Updates - By filing the 2024 20-F, the company believes it has regained compliance with Nasdaq Listing Rule 5250(c)(1), which may eliminate the need for a hearing regarding a delisting determination [2]. - The company is awaiting formal confirmation from Nasdaq regarding its compliance status [2]. Environmental Considerations - To reduce environmental impact, the company encourages shareholders to read the annual report in digital format, although hard copies are available upon request [4].

Castellum, Inc. to Participate in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow” Castellum, Inc. (NYSE-American: CTM), announces that its Chief Executive Officer, Glen Ives, has been invited to present at the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow,” presented by Maxim Group LLC, on Tuesday, June 3rd – Thursday, June 5th at 9:00 a.m. EDT - www.castellumus.com VIENNA, Va., June 02, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-America ...

Core Insights - Brazil Potash Corp. has made significant progress in governance, commercial partnerships, construction, and financial initiatives for the Autazes Potash Project, which is crucial for Brazil's agricultural security [1][2] Group 1: Achievements and Progress - The company has established a $75 million equity line of credit with Alumni Capital, enhancing its capital access for project advancement [5] - Brazil Potash signed a Memorandum of Understanding (MOU) with Keytrade AG for potential offtake of up to one million tons per year, moving towards approximately 1.5 million tons of committed production [6] - The company has strengthened government relations through strategic meetings with key stakeholders, including the Amazonas State Governor and the Mura Indigenous Council [6] Group 2: Leadership and Governance - Mayo Schmidt was appointed as Executive Chairman in January 2025, bringing experience from Nutrien, the world's largest fertilizer company [6] - Christian Joerg was added to the Board of Directors, contributing three decades of experience in agricultural commodities and international trade finance [6] - The Advisory Board was expanded with Marcelo Lessa, a former IFC/World Bank executive with extensive project financing expertise [6] Group 3: Construction and Operational Advancements - The company received approval to begin fauna rescue and vegetation suppression activities, enabling subsequent shaft sinking operations [6] - Site preparation work at the future port terminal has been completed, marking a critical infrastructure milestone [6] - Water extraction installation licenses have been converted to full operational permits, securing water supply for construction and operations [6] Group 4: Market Context and Future Outlook - Brazil Potash aims to produce up to 2.4 million tons of potash annually, potentially supplying approximately 20% of Brazil's current potash demand [7] - The project is expected to reduce Brazil's reliance on potash imports while mitigating approximately 1.4 million tons per year of greenhouse gas emissions [7]

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor typesThe co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners’ expertise, resources and global footprint to accelerate BNT327’s path towards potential regulatory approvals and market launchesBioNTech and Bristol Myers ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, a ...

Atlanta, June 02, 2025 (GLOBE NEWSWIRE) -- Piedmont Office Realty Trust, Inc. ("Piedmont” or “the Company") (NYSE:PDM), an owner of Class A office properties located primarily in the Sunbelt, announced today, that the Company is participating in this week’s Nareit REITWeek Investor Conference in New York City. The Company has completed over 500,000 square feet of leasing thus far in the second quarter, with 350,000 square feet related to new tenants. Approximately 70% of the new tenant leases are for curren ...

YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make i ...

Core Viewpoint - Hyperscale Data, Inc. is strategically divesting non-core investments to focus on its data center business, particularly in developing its Michigan facility to support high-performance computing and AI applications [1][2][3]. Group 1: Financial Transactions - The company sold its minority equity interest in a privately held pharmaceutical company for gross proceeds of $4.65 million, having initially invested $1.5 million in the equity position [1]. - This transaction aligns with the company's strategy to concentrate capital and resources on its primary asset, a 617,000 square foot data center in Michigan [2]. Group 2: Data Center Development - The Michigan data center is being developed to support high-performance computing workloads, including AI applications [2]. - The company plans to expand the facility's power capacity from approximately 30 megawatts (MW) to 300 MW, with an additional 40 MW from a local natural gas utility, bringing the total expected capacity to approximately 340 MW [3]. Group 3: Future Plans - The company expects to divest its subsidiary Ault Capital Group, Inc. by December 31, 2025, focusing solely on data center operations and potentially continuing Bitcoin mining [7]. - The divestiture will occur through the exchange of Series F Preferred Stock for shares of Class A and Class B Common Stock of ACG, allowing stockholders to become shareholders of ACG upon completion [9].